Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced…
-
QualityStocksNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Among Early Adopters of Bitcoin Treasury Strategies Amid Growing Trend
SolarBank Corporation joins a group of 61 public companies adopting bitcoin treasury strategies. The company…